{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non-Hematological Grade 3- Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Non Hematological Grade 3- Syncope"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Pulmonari emboli"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hematological Grade 3- Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Cough"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Bacteremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Anorectal Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Rectal Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non Hematological Grade 3- Rib Pain"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Toxicities with a grade 3 nonhematologic or grade 4 hematologic toxicities according to CTCAE, version 4. Grade 3 and estimated with a 95% credible interval. Summary statistics will be provided for continuous variables.","groups":[{"description":"Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)","id":"OG000","title":"Tivantinib Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Toxicities of Single Agent Tivantinib: Grade 3 Nonhematologic or Grade 4 Hematologic Toxicities According to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4","type":"PRIMARY","unitOfMeasure":"Participants"}